Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeu (NQ: ALDX )

9.340 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 9.340
Bid (Size) 7.430 (1)
Ask (Size) 10.29 (1)
Prev. Close 9.340
Today's Range 9.340 - 9.340
52wk Range 2.860 - 10.88
Shares Outstanding 58,576,350
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recap: Aldeyra Therapeutics Q1 Earnings
 
Via Benzinga
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire

Performance

YTD
+34.20%
+34.20%
1 Month
-7.34%
-7.34%
3 Month
+38.17%
+38.17%
6 Month
+71.06%
+71.06%
1 Year
+202.27%
+202.27%

More News

Read More
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
Via FinancialNewsMedia
Exposures COVID-19
Earnings Outlook For Aldeyra Therapeutics
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Week In Charts: 0DTE Options - Too Good To Be True?
Via Talk Markets
Short Volatility Alert: Aldeyra Therapeutics
Via Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Via Benzinga
Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Chart Of The Day: Aldeyra - Skyrocketing
Via Talk Markets
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) Records 52-Week High Monday Morning
Via Investor Brand Network
Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough
From Aldeyra Therapeutics, Inc.
Via Business Wire
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Via Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
Via Benzinga
UBS, Credit Suisse And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients
Via Benzinga
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
Via Benzinga
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
From Aldeyra Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.